Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2195908 | 0.99 | SYK (0.45) | SYKFLT1EPHA2KDREPHB4 | |
| SCHEMBL5548307 | 0.82 | FLT1 (0.41) | FLT1EPHA2KDREPHB4NOS3 | |
| SCHEMBL30354902 | 0.82 | NOS3 (0.50) | SYKFLT1EPHA2KDREPHB4 | |
| SCHEMBL30354850 | 0.81 | GAA (0.53) | SYKFLT1EPHA2KDREPHB4 | |
| SCHEMBL4034116 | 0.79 | NOS3 (0.40) | SYKFLT1EPHA2KDREPHB4 | |
| SCHEMBL27298989 | 0.79 | FLT1 (0.41) | FLT1EPHA2KDREPHB4NOS3 | |
| SCHEMBL4030081 | 0.78 | RAB9A (0.57) | SYKNOS1S1PR4MRGPRX4NPC1 | |
| SCHEMBL9873609 | 0.77 | FLT1 (0.38) | SYKFLT1EPHA2KDREPHB4 | |
| SCHEMBL6237515 | 0.77 | MAPT (0.48) | S1PR4NPC1MAPTRAB9AKMT2A | |
| SCHEMBL27096875 | 0.77 | SYK (0.46) | SYKEGFRS1PR4MRGPRX4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1802633-A1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044524-A1 | BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | SYK 2763/4885FLT1 2782/4885EPHA2 2476/4885 |
| US-20080132497-A1 | Novel Heterocycles | HRAS, CCNC, PCNA | SYK 2831/4885FLT1 1616/4885EPHA2 3254/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | SYK 1194/4885FLT1 172/4885EPHA2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.